Three studies show how finerenone fares for nondiabetic CKD, across CKD etiologies

Three major studies showed that finerenone could provide kidney and CV benefits for a wider range of patients with chronic kidney disease, according to a press release. Finerenone (Kerendia, Bayer), a nonsteroidal selective mineralocorticoid receptor antagonist, is approved by the FDA for reducing kidney and CV risks in patients with CKD and type 2 diabetes. The three studies suggest finerenone